NOVADIP raises €10.4 million to fund NVD003’s final regulatory mile

Belgian biotech Novadip Biosciences has secured €10.4 million through a convertible loan from New Science Ventures and its existing investors. The financing will support the completion of the pivotal Phase 3 trial of NVD003, its cell therapy for severe bone defects, and preparations for a US regulatory submission. After thirteen years of development, the company is entering the narrowest section of the path: proving the treatment’s efficacy, securing approval and turning personalized production into an industrial operation.

Twelve children. Much of Novadip Biosciences’ future now rests on this unusually small group. The Belgian company is conducting a pivotal Phase 3 trial in Europe and the United States to evaluate NVD003 in congenital pseudarthrosis of the tibia, a rare pediatric condition that prevents the bone from healing and can lead to amputation after repeated unsuccessful procedures.

To finance this final clinical stage, Novadip has secured €10.4 million through a convertible loan. The round was led by US-based New Science Ventures, with participation from Fund+, Wallonie Entreprendre, VIVES Fund, ORSA Tech, Sambrinvest, Noshaq and Invest.BW, all existing investors in the company.

The transaction follows an initial €9.6 million convertible loan secured in 2025. Novadip has therefore raised €20 million since June 2025 to carry NVD003 through its next clinical and regulatory milestones.

The amount may appear modest for a biotech conducting a transatlantic Phase 3 trial, but it represents only one part of the financing structure. Closing the round also enables Novadip to draw down the final tranche of an €18 million venture debt facility granted by the European Investment Bank in 2023 with support from InvestEU.

Scientific evidence must now become regulatory evidence

NVD003 is an autologous cell therapy, meaning that it is manufactured using the patient’s own cells. Novadip collects mesenchymal stem cells derived from adipose tissue, turns them into a three-dimensional osteogenic graft and combines them with mineral particles before implanting the product into the area where the bone has failed to heal.

The technology stems from research conducted by Denis Dufrane at UCLouvain and Cliniques universitaires Saint-Luc. Since its foundation in 2013, Novadip has gradually built a portfolio of products around the platform, targeting complex bone defects, bone non-union and certain spinal fusion procedures.

Early results from NVD003 have been encouraging, although they still involve a limited patient population. In January 2025, the company reported that 15 of the 17 patients treated, including both adults and children, had achieved bone union. In congenital pseudarthrosis of the tibia, the data covered eight children: four enrolled in a Phase 1b/2a trial and four treated through compassionate-use programs. Seven achieved fracture healing.

These results enabled Novadip to move into Phase 3, but they do not yet provide definitive evidence of the treatment’s efficacy. The patients were treated under different protocols, without a control group, while the company attributed the observed failures to mechanical instability following surgery. The pivotal trial is intended to isolate the product’s effect, standardize its surgical use and generate the evidence required by regulators.

A Phase 3 trial involving twelve children

The rarity of the disease requires a trial on an unusual scale. Novadip plans to recruit twelve children across eight European and US institutions, including Cliniques universitaires Saint-Luc in Brussels, Necker-Enfants Malades Hospital in Paris, Amiens-Picardie University Hospital, Mayo Clinic and Phoenix Children’s Hospital.

The first two patients received NVD003 in February and March 2026, in Belgium and the United States respectively. The trial will assess clinical and radiological bone healing twelve months after graft surgery. The children will then be monitored for an additional four years to evaluate the treatment’s durability and safety.

At the beginning of 2025, Novadip was still targeting a 2027 market launch. A one-year delay is not unusual in the development of a cell therapy, particularly for a very rare pediatric disease. The new financing is intended to give the company the resources required to reach the regulatory submission stage.

The financing defers dilution and brings the next round closer

Using two convertible loans allows Novadip to avoid setting a new valuation immediately. Investors provide capital in the form of debt, with the option of later converting their claims into shares, generally during a subsequent financing round or once specific milestones have been reached.

At this stage, the round relies largely on existing shareholders and Belgian financial institutions. New Science Ventures, a US investor specializing in life sciences and advanced technologies, is leading the transaction, but no pharmaceutical group or global cell therapy specialist has been announced.

“This transaction gives us the resources needed to advance NVD003 through major clinical and regulatory milestones, including completion of our pivotal Phase 3 trial in congenital pseudarthrosis of the tibia and preparation of our US regulatory filings,” said Denis Dufrane, co-founder and CEO of Novadip.

A voucher potentially worth more than the financing round

Novadip’s financial equation includes another asset that remains conditional but could prove highly valuable. If the FDA approves NVD003 for congenital pseudarthrosis of the tibia, the company could receive a Rare Pediatric Disease Priority Review Voucher.

The voucher allows its holder to request an expedited FDA review of another drug. It can either be used by the company that receives it or sold to another pharmaceutical group. The US program has been extended until September 30, 2029.

The market places a high value on these regulatory assets. Zevra Therapeutics sold a voucher for $150 million in 2025, while Fortress Biotech and its subsidiary Cyprium announced the sale of another PRV for $205 million in February 2026.

Novadip will only be eligible for the voucher if NVD003 is approved and the company meets all the program’s requirements. It should therefore not be treated as an asset already secured. Its potential value nevertheless far exceeds the €10.4 million announced today. A sale could finance part of the commercial launch or the development of NVD003 in adult indications.

After the clinic comes the industrial challenge

Congenital pseudarthrosis of the tibia represents a narrow initial indication. According to data cited by Novadip, the condition affects between one in 140,000 and one in 250,000 live births. The economic potential claimed by the company therefore depends less on this population alone than on extending the technology to more common bone defects in adults.

Novadip plans to launch another Phase 3 trial of NVD003 in adults with critical-size bone defects, targeting approval in 2031. In parallel, it is developing NVDX3, an allogeneic bone graft material manufactured from donor cells. Phase 1b/2a trials of this second program have been completed in trauma surgery and lumbar spinal fusion, while the FDA has authorized the launch of a Phase 2b/3 trial.

This is where the autologous nature of NVD003 becomes decisive. Each graft must be manufactured from the cells of the individual patient. During the Phase 3 trial, the products are prepared in Belgium before being shipped to surgical centers in Europe and the United States. The program is therefore already testing part of the future industrial model: cell collection, processing, quality control, transport and implantation.

Moving from twelve patients to international commercialization will nevertheless require a different scale. Novadip will have to increase capacity without compromising quality, secure the timelines between cell collection and surgery, train hospital centers and, most likely, move part of its production closer to the US market.

Since its foundation, Novadip has raised €137 million in equity and non-dilutive financing. The €10.4 million announced today will fund the narrowest stage of its development, where thirteen years of research must become a regulatory filing before industrialization can begin.